

Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting *JunB* and *JunD*

Esmerina Tili¹, Jean-Jacques Michaille^{1,2,*}, Brett Adair¹, Hansjuerg Alder¹, Emeric Limagne², Cristian Taccioli¹, Manuela Ferracin³, Dominique Delmas², Norbert Latruffe² and Carlo M.Croce¹

¹Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Biomedical Tower, 460 West 12th Avenue, Columbus, OH 43210, USA, ²Laboratoire de Biochimie Métabolique et Nutritionnelle-INSERM U866, Université de Bourgogne, Faculté Gabriel, 6 Bd. Gabriel, 21000 DIJON, France and ³Dipartimento di Medicina sperimentale e diagnostica, sez. Microbiologia, Università di Ferrara, presso Il Cubo, Via Fossato di Mortara, 70, 44100 Ferrara, Italia

*To whom correspondence should be addressed. Tel: +33 380 39 62 11; Fax: +33 380 39 62 50; Email: jean-jacques.michaille@u-bourgogne.fr
Correspondence may also be addressed to Carlo M.Croce. Tel: +1 614 292 3063; Fax: +1 614 292 3558; Email: carlo.croce@osumc.edu

An inflammatory component is present in the microenvironment of most neoplastic tissues, including those not causally related to an obvious inflammatory process. Several microRNAs, and especially miR-155, play an essential role in both the innate and adaptative immune response. Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural antioxidant with anti-inflammatory properties that is currently at the stage of preclinical studies for human cancer prevention. Here, we establish that, in human THP-1 monocytic cells as well as in human blood monocytes, resveratrol upregulates miR-663, a microRNA potentially targeting multiple genes implicated in the immune response. In THP-1 cells, miR-663 decreases endogenous activator protein-1 (AP-1) activity and impairs its upregulation by lipopolysaccharides (LPS), at least in part by directly targeting *JunB* and *JunD* transcripts. We further establish that the downregulation of AP-1 activity by resveratrol is miR-663 dependent and that the effects of resveratrol on both AP-1 activity and *JunB* levels are dose dependent. Finally, we show that resveratrol impairs the upregulation of miR-155 by LPS in a miR-663-dependent manner. Given the role of miR-155 in the innate immune response and the fact that it is upregulated in many cancers, our results suggest that manipulating miR-663 levels may help to optimize the use of resveratrol as both an anti-inflammatory and anti-cancer agent against malignancies associated with high levels of miR-155.

Introduction

Epidemiological studies suggest that as many as 25% of all cancers may be due to chronic inflammation (1–4). The connection between inflammation and cancer consists of an extrinsic pathway, driven by inflammatory conditions that increase cancer risk, and an intrinsic pathway, driven by genetic alterations that cause inflammation and neoplasia (2). Furthermore, inflammatory mediators released by cancer-related inflammation can induce genetic instability, leading to the accumulation of random genetic alterations in cancer cells (3). Beside resident cell types, such as fibroblasts and adipocytes, tumor microenvironment contains various inflammatory cell types infiltrating the tumor area in response to inflammatory stimuli, such as macrophages, neutrophils and mast cells (5–7). Tumor-associated macrophages are thought to play key roles in the production of various growth factors, angiogenic factors, proteinases, chemokines and

cytokines, through cross talks with cancer cells and other tumor stromal cells (8–10). These factors in turn stimulate cell migration/motility, proliferation, survival, angiogenesis and metastasis, resulting in a dynamic environment that favors the progression of cancer, thus affecting the clinical outcome of malignant tumors (7). Tumor-associated macrophages have thus been described as 'obligate partners for tumor cell migration, invasion and metastasis' (11). Namely, in a genetic model of breast cancer in macrophage-deficient mice, the tumors developed normally but were unable to form pulmonary metastases in the absence of macrophages (12). As tumor metastasis is responsible for ~90% of all cancer-related deaths, a better understanding of inflammation regulatory mechanisms may potentially allow to optimize the use of anticancer drugs that may target tumor-associated macrophages and lower tumor-specific inflammatory response (7).

MicroRNAs (miRNAs) are short non-coding RNAs that regulate the translation and/or degradation of target messenger RNAs (13), and whose molecular malfunctions are associated with major pathologies such as cancers (14) or autoimmune diseases (15). Several miRNAs have been implicated in the control of hematopoietic lineage differentiation (16–18). Among them, *miR-155* has been implicated in the regulation of myelopoiesis and erythropoiesis, Type 1 helper T-cells differentiation, B cell maturation, IgG1 production, somatic hypermutations, gene conversion, class switch recombination, B- and T-cell homeostasis as well as in the regulation of the innate immune response [(19) and references therein]. Thus, *miR-155* levels increase following lipopolysaccharides (LPS) treatment of THP-1 cells or Raw-264 macrophages, and *miR-155* transgenic mice show enhanced sensibility to LPS-induced endotoxin shock (20–22). In contrast, *miR-155*-knockout mice are unable to mount a proper T-cell or B-cell immune responses (23). On the other hand, the immune response is limited by the upregulation of anti-inflammatory miRNAs such as *miR-146a* and *miR-146b*, which target interleukin-1 receptor-associated kinase 1 and tumor necrosis factor receptor-associated factor 6 (20,24). Importantly, several reports have recently established a direct link between elevated levels of *miR-155* expression and the formation and development of tumors such as leukemias and breast, lung or gastric cancers (19). Elevated *miR-155* levels are linked with enhanced cell proliferation (16,17), transgenic mice with B cells overexpressing *miR-155* develop B-cell leukemia (25) and a sustained expression of *miR-155* in hematopoietic stem cells causes a myeloproliferative disorder (26).

Resveratrol (trans-3,4',5-trihydroxystilbene) is a dietary polyphenolic, non-flavonoid antioxidant derived from grapes, berries, peanuts and other plant sources. Resveratrol has various health benefits, such as cardiovascular and cancer preventive properties (27–29), and it is currently at the stage of preclinical studies for human cancer prevention (29,30). Some of the resveratrol protective activities are associated with the downregulation of the inflammatory response through inhibitory effects on transcription factors like nuclear factor-kappaB or activator protein-1 (AP-1) components c-Jun and c-Fos, including the inhibition of the release of pro-inflammatory mediators such as reactive oxygen, nitrogen species and prostaglandin E2 or of enzymes implicated in their synthesis (27,31,32). In adipocytes, resveratrol inhibits the production of the tumor necrosis factor-induced monocyte chemoattractant protein-1, which has been implicated in chronic low-grade inflammation, a key feature of obesity type 2 diabetes (33).

To date, it is not known if the antitumor and anti-inflammatory effects of resveratrol may rely on the modulation of expression of either pro-inflammatory or anti-inflammatory miRNAs. To address this question, we pretreated human THP-1 monocytes with resveratrol before challenging them with LPS. We show that resveratrol impairs the upregulation of oncogenic pro-inflammatory *miR-155* by LPS, at

Abbreviations: AP-1, activator protein-1; LPS, lipopolysaccharides; miRNA, microRNA; PCR, polymerase chain reaction; UTR, untranslated region.

least in part through the upregulation of *miR-663*, a miRNA targeting *JunB* and *JunD* transcripts.

Materials and methods

Microarray analyses

RNAs extracted with TRIzol (Invitrogen, Carlsbad, CA) were subsequently subjected to DNase digestion (Turbo-DNase; Ambion, Austin, TX). Affymetrix and miRNA microarray analyses were done at the Ohio State University microarray facility.

Cell culture, treatments and transfection

THP-1 cells were electroporated using the AMAXA Kit (Lonza, Allendale, NJ). LPS stimulation was done with *Salmonella enteritidis*-derived LPS (100 ng/ml; Sigma-Aldrich, St Louis, MI). Whenever needed, cells were pre-treated 14 h with either the vehicle (ethanol) or resveratrol 50 μ M.

Isolation and treatment of human blood monocytes

Human peripheral blood monocytes were obtained from healthy donors. Monocytes were enriched using a Monocyte Isolation Kit with autoMACS Separator according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). They were subsequently grown for 24 h in RPMI 1640 medium with glutamax-I (Lonza) supplemented with 10% fetal bovine serum (Lonza) in standard conditions and exposed to 100 ng/ml colony stimulating factor-1. Cell viability was assessed using Trypan blue. Monocytes were then treated for 14 h with either the vehicle or resveratrol 30 μ M before RNA extraction.

RNase-protection assays

Assays were performed using the *mirVana* miRNA Probe Construction Kit and the *mirVana* miRNA Detection Kit from Ambion. RNAs were incubated overnight at 46°C in the presence of 8×10^4 c.p.m. of antisense RNA probe and then digested for 40 min at 37°C using a 1/50 dilution of the provided RNase A/RNase T1 solution.

Preparation of clones and mutagenesis

The 3'-untranslated regions (UTRs) of *JunB* and *JunD* were cloned by polymerase chain reaction (PCR) from HEK-293 cells genomic DNA and then inserted downstream of the *Luciferase* gene in the *XbaI* site of the *pGL3-Control* vector (Promega, Madison, WI). *MiR-663* target sites were mutated using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene; Agilent Technologies, Santa Clara, CA). Sequences of the mutated *miR-663* target sites in *JunB* and *JunD* 3'-UTRs are given in supplementary Table II, available at *Carcinogenesis* Online.

Luciferase assays

Cells (1×10^6) in six-well plates were transfected with 0.4 μ g of DNA (Promega *pGL3-Control* vector or derived constructs), *pre-miR-663* or *663-I* (50 nM final; Ambion) and 20 ng of *Renilla* Luciferase control vector (*pRL-TK* from Promega). Assays were performed 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to *Renilla* luciferase activity. The pre-miR Precursor Molecule-Negative Control #1 (Ambion) was used as a pre-miR control. AP-1 activity was measured using the Signal AP-1 Luciferase Reporter Assay Kit (Super Array Bioscience Corporation; SABioscience, Qiagen, Valencia, CA).

Quantitative real-time PCR

MiR-155 quantitative real-time PCRs were performed using TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA). Values were normalized using either *RNU-44* or *RNU-48*. Real-time PCRs were run in triplicates from three different complementary DNAs.

Western blots

Anti-JunB, anti- α -tubulin and anti-glyceraldehyde-3-phosphate dehydrogenase antibodies were from Cell Signaling Technology (Danvers, MA). Anti-JunD was from Abcam (Cambridge, MA). Anti-cMaf was from Santa Cruz Biotechnology (Santa Cruz, CA). The relative intensities of the bands of interest, preably normalized to glyceraldehyde-3-phosphate dehydrogenase or α -tubulin, are given under each panel in percent of the respective control sample.

Results

Resveratrol upregulates miR-663

Affymetrix microarrays showed that resveratrol modulated the levels of a number of transcripts in THP-1 cells, expectedly upregulating

those coding for anti-proliferation factors, whereas downregulating those coding for pro-proliferation factors (MIAME E-TABM-782). The most significant change was a roughly 20 times upregulation of *LOC284801* transcripts, which contain the sequence of *pre-miR-663* and thus represent *miR-663* primary transcripts. *In silico* analysis using TargetScan (<http://www.targetscan.org/>) showed that *miR-663* potentially targets transcripts of several genes implicated in the immune response (supplementary Table I is available at *Carcinogenesis* Online), and especially *JunB*, *JunD* and *FosB*, which encode AP-1 factors known to activate many cytokine genes in partnership with nuclear factor of activated T-cells factors (34).

Due to *miR-663* base composition (20 CG/22 nt), no TaqMan probe is presently available for quantitative real-time PCR. However, miRNA microarrays also showed that resveratrol upregulates *miR-663* by roughly 75% (MIAME E-TABM-780). This was further confirmed by RNase-protection assays (Figure 1). Furthermore, miRNA microarrays (MIAME E-TABM-1035) also showed that a lower dose (30 μ M) of resveratrol still induced similar changes in miRNA populations from human blood monocytes, with the levels of *miR-663* increasing roughly by 30%.




Fig. 1. Resveratrol increases the levels of both *miR-663* and *LOC284801* transcripts. Total RNAs (0.6 μ g) extracted from THP-1 cells treated 14 h with the vehicle (V) or resveratrol (R) were hybridized with a radiolabelled RNA antisense probe (P1, P2, P3 or U6) in the presence of 4.4 μ g of yeast transfer RNA. The schematic structure of the *LOC284801* locus, whose transcripts represent *miR-663* primary transcripts, is presented on the unscaled top drawing. Open and filled boxes represent *miR-663* precursor (*pre-miR-663*) and mature *miR-663*, respectively. P1 is located 1308 bp upstream of *pre-miR-663* and corresponds to one of the Affymetrix probes. P2 is located 151 bp upstream of *pre-miR-663*. *Pre-miR-663* and *miR-663*, respectively, generate 40 and 22 nt long protected fragments from P3, which corresponds to one of the miRNA microarrays probes. The relative intensity of the signal following resveratrol treatment is given between parentheses in percent of the vehicle sample, calculated using *U6snRNA* as an internal control. The efficiency of RNase digestion was assessed in parallel (two left lanes). C–, no RNase (15-fold dilution); C+, RNase; Nd, non-digested; Pr, protected fragment.

MiR-663 targets *AP-1* activity as well as *JunB* and *JunD* transcripts
 In the presence of LPS, both the surge of AP-1 activity and the upregulation of *JunB*, an AP-1 factor whose transcript levels peak within the first hour of LPS challenge (35) were impaired by *miR-663* overexpression in THP-1 cells (Figure 2A and B, respectively). This indicates that transcripts encoding *JunB* and possibly other AP-1 factors upregulated during the mounting of the inflammatory response to LPS are targeted, directly or indirectly, by *miR-663*. In addition, a *miR-663* inhibitory RNA (*663-I*) increased both AP-1 activity and *JunB* levels in non-challenged THP-1 cells, suggesting that *miR-663* normally works to impair any sudden surge of AP-1

activity or *JunB* levels in resting cells (Figure 2A and B). Finally, luciferase assays using constructs containing *JunB* 3'-UTR with wild-type or mutated *miR-663* target sites provided strong evidence that *miR-663* targets *JunB* 3'-UTR directly (Figure 2C). Furthermore, the effects of both *miR-663* and *663-I* on *JunD* levels and those of *miR-663* on the expression of a construct containing the 3'-UTR of *JunD*, a gene encoding another AP-1 factor, were quite similar (supplementary Figure 1A and B, respectively, is available at *Carcinogenesis* Online). Together, these results establish *miR-663* as a new regulator of *JunB* and *JunD* levels and more generally of AP-1 activity.

Of note, *663-I* failed to further increase AP-1 activity or *JunB* levels following LPS challenge (Figure 2A and B, respectively). This suggested that either AP-1 activity and *JunB* already reached their maximum possible levels under LPS challenge in the presence of control RNA or that the innate immune response might reduce *miR-663* endogenous levels. Indeed, the levels of both *miR-663* and *pre-miR-663* decreased roughly 25% within 30 min of LPS challenge (supplementary Figure 2 is available at *Carcinogenesis* Online). Of note, the levels of *pri-miR-663* remained unchanged, suggesting that LPS signaling may decrease the processing of *pri-miR-663* by Droscha without impacting the transcription of the *miR-663* host gene.




Fig. 2. *miR-663* decreases AP-1 activity and targets *JunB*. (A) AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA, *pre-miR-663* (663) or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 h). Values represent the mean \pm standard deviation ($n = 3$). * and **, significantly different from the corresponding mock-challenged sample, * $P < 0.001$ and ** $P < 0.0005$. ^o, significantly different from LPS-challenged Control, $P < 0.0008$. #, significantly different from mock-challenged Control, $P < 0.0001$. (B) The levels of *JunB* in THP-1 cells transfected with either a pre-miR Control, *pre-miR-663* or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 h), were determined by western blotting. (C) Effects of *pre-miR-663* on *Luc-JunB* constructs, both in sense and antisense orientation. Sequences of the two mutated *miR-663* target sites in *JunB* sense constructs (M663) are given in supplementary Table II, available at *Carcinogenesis* Online. Values represent the mean \pm standard deviation ($n = 4$). * and **, significantly different from Pre-miR-Control, * $P < 0.001$ and ** $P < 0.0001$.

Resveratrol decreases AP-1 activity through *miR-663*

As resveratrol decreases the levels and binding activities of AP-1 factors c-Jun and c-Fos (32), whose transcripts do not contain any *miR-663* target site, we then checked if it may also control AP-1 activity through the upregulation of *miR-663*. As expected, resveratrol decreased AP-1 activity in non-challenged THP-1 cells (Figure 3A). This effect was dose dependent (supplementary Figure 3A is available at *Carcinogenesis* Online). Resveratrol also proved capable to decrease *JunB* levels in unchallenged cells in a dose-dependent manner (supplementary Figure 3B is available at *Carcinogenesis* Online). Furthermore, resveratrol still decreased AP-1 activity following LPS challenge (Figure 3A). Also, in agreement with the results of Figure 2A, *663-I* sharply increased AP-1 activity in untreated non-challenged cells, but not following LPS treatment (Figure 3A). Importantly, *663-I* significantly impaired the downregulating effects of resveratrol on AP-1 activity following LPS challenge, indicating that *JunB*, *JunD* and/or possibly *FosB* levels decreased as a consequence of the upregulation of *miR-663* by resveratrol. Accordingly, resveratrol impaired *JunB* upregulation following LPS-challenge (Figure 3B). *663-I*, however, did not significantly impair the downregulation of AP-1 activity by resveratrol in non-challenged cells (Figure 3A), suggesting that the effects of resveratrol in resting cells are mainly directed on AP-1 components not targeted by *miR-663*, presumably c-Jun and c-Fos. Thus, the upregulation of *miR-663* may allow resveratrol to change the composition, and most probably the activity, of AP-1 dimers following LPS challenge.

We then checked if the downregulation of *JunB* by resveratrol was *miR-663*-dependent. As shown previously for AP-1 activity (Figure 3A), *663-I* increased sharply *JunB* levels in untreated non-challenged THP-1 cells but proved incapable of increasing *JunB* levels further following LPS challenge of untreated cells (Figure 3C). Of note, when cells had been preably transfected, the upregulation of *JunB* by LPS was roughly 3-fold less (compare panels B and C of Figure 3). This suggests that transfection might by itself elicit some kind of response, with the result of decreasing the sensibility and thus the further response of THP-1 cells to LPS. Finally, *663-I* seemingly increased slightly the capability of resveratrol to bring down *JunB* levels following LPS challenge. This counterintuitive result was not due to a lack of targeting of *JunB* transcripts by *miR-663*. Namely, as shown by luciferase assays, resveratrol as expected decreased the expression of *Luc-JunB* (Figure 3D) and *Luc-JunD* (supplementary Figure 1C is available at *Carcinogenesis* Online) constructs in a *miR-663*-dependent manner, thus giving a further evidence that it upregulates *miR-663*. It might be that *663-I* could also impair the targeting of transcripts encoding some unidentified repressor of *JunB* by *miR-663*. Nevertheless, all together, these results indicate that




Fig. 3. Resveratrol decreases AP-1 activity in a *miR-663*-dependent manner. (A) AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h. Values represent the mean \pm standard deviation ($n = 3$). *, significantly different from the corresponding mock-challenged sample, $P < 0.005$. o and oo, significantly different from the corresponding vehicle-treated sample, o, $P < 0.03$, oo, $P < 0.001$. #, significantly different from the LPS-challenged resveratrol-treated Control, $P < 0.005$. ##, significantly different from the mock-challenged Vehicle-treated Control, $P < 0.0005$. (B) The effects of a 14 h resveratrol pretreatment on the accumulation of JunB following LPS challenge were determined by western blotting. (C) The levels of JunB in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h, were determined by western blotting. (D) Effects of a 14 h resveratrol treatment on the expression of wild-type (WT) or mutated (M663) *Luc-JunB* constructs in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I). Values represent the mean \pm standard deviation ($n = 4$). * and **, significantly different from the corresponding WT/Control, * $P < 0.007$ and ** $P < 0.0009$.

resveratrol can downregulate AP-1 activity by both *miR-663*-dependent and *miR-663*-independent mechanisms.

Resveratrol impairs the upregulation of oncogenic pro-inflammatory *miR-155* by LPS at least partly through *miR-663*

The upregulation of *miR-155* is the hallmark of inflammatory response following LPS treatment of THP-1 cells (21) or Raw-264 macrophages (22). In B cells, AP-1 factors such as JunB and FosB transcriptionally activate *BIC*, whose transcripts represent *miR-155* primary RNAs (36). Given their effects on AP-1 activity, *miR-663* and resveratrol would thus be expected to impair the upregulation of *miR-155* by LPS. Indeed, transfecting THP-1 cells with *pre-miR-663* limited *miR-155* upregulation following LPS challenge (Figure 4A). In contrast, *663-I* remained without obvious effects, which was probably due to the downregulation of *miR-663* by LPS (supplementary Figure 2 is available at *Carcinogenesis* Online) and also possibly to the fact that the maximum possible levels of *miR-155* were already reached in LPS-challenged control cells. Accordingly, resveratrol impaired the LPS-induced upregulation of *miR-155* (Figure 4B) and consequently suppressed the downregulation of c-Maf, a validated target of *miR-155* (23) (Figure 4C). In addition, *663-I* slightly but significantly limited the capability of resveratrol to downregulate *miR-155* (Figure 4D). Thus, some of the effects of resveratrol on oncogenic pro-inflammatory *miR-155*, and therefore also presumably some of its antitumor effects, are due to its upregulation of *miR-663*.

Discussion

Our study provides the very first data concerning the effects of resveratrol on miRNAs and its ability to both upregulate *miR-663* and

downregulate oncogenic pro-inflammatory *miR-155*. It provides strong support that: (i) *miR-663* targets *JunB* and *JunD* transcripts, consequently decreasing JunB and JunD levels as well as AP-1 activity; (ii) *miR-663* also potentially targets transcripts encoding several other factors needed for the innate immune response; (iii) the downregulation of AP-1 activity by resveratrol is *miR-663*-dependent and (iv) resveratrol impairs the upregulation of *miR-155* by LPS at least in part by upregulating the anti-inflammatory *miR-663*.

Transcripts from the *LOC284801* locus on chromosome 20, which represent *miR-663* primary RNAs, showed the highest statistically significant level change following resveratrol treatment of THP-1 cells, as deduced from Affymetrix microarray analysis. Although no probe is presently available to follow *miR-663* accumulation by quantitative real-time PCR, due to its >92% CG content, miRNA microarrays, RNase protection and luciferase assays provided independent confirmations of the upregulation of mature *miR-663* by resveratrol. As it is the case for many other miRNAs, *miR-663* upregulation was not proportional to that of its primary transcripts, which probably reflects posttranscriptional regulations.

Our results confirm the downregulation of AP-1 activity by resveratrol. However, while previous reports mainly focused on resveratrol effects on c-Jun and c-Fos, our results show that resveratrol can specifically target JunB and JunD by increasing *miR-663* levels and suggest that the same miRNA could also target *FosB* transcripts. This is an important result, for AP-1 factors include c-Jun, JunB, JunD, FosB, Fra-1 and Fra-2, as well as Jun dimerization partners JDP1 and JDP2 or the closely related ATF2, LRF1/ATF3 and B-ATF, so that potentially ~18 different dimeric combinations may be formed. Thus, the capability of resveratrol to upregulate *miR-663* to specifically target a subset of AP-1 dimers might have profound effects on the levels of expression of promoters to whom different AP-1 factors can compete




Fig. 4. Resveratrol opposes the upregulation of *miR-155* at least in part by upregulating *miR-663*. (A) The relative expression of *miR-155* in THP-1 cells transfected with either a Control RNA, *pre-miR-663* (663) or a *miR-663* inhibitor RNA (663-I) and subsequently challenged or not with LPS for 6 h were determined by quantitative real-time PCR. Values represent the mean \pm standard deviation ($n = 3$). *, significantly different from the corresponding mock-challenged sample, $P < 0.06$. o, significantly different from LPS-challenged Control, $P < 0.005$. (B) Time-course of *miR-155* expression in LPS-challenged THP-1 cells preably treated with vehicle or resveratrol for 14 hours, as determined by quantitative real-time PCR. Values represent the mean \pm standard deviation ($n = 3$). (C) The levels of c-Maf in THP-1 cells pretreated with vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h were determined by western blotting. (D) The relative expression of *miR-155* in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I) and then pretreated with vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h were determined by quantitative real-time PCR. Values represent the mean \pm standard deviation ($n = 3$). * and **, significantly different from the corresponding mock-challenged sample, $*P < 0.014$ and $**P < 0.004$. o and oo, significantly different from LPS-challenged vehicle-treated Control, $oP < 0.02$ and $ooP < 0.0001$. #, significantly different from LPS-challenged resveratrol-treated Control, $P < 0.05$.

to bind to. Due to the many roles of AP-1 factors both in inflammation (37) and cancer (38,39), the specific targeting of genes encoding a subset of AP-1 factors, by changing the composition of AP-1 dimers on key promoters, may possibly explain some of the resveratrol anti-inflammatory and anticancer properties. However, while *663-I* increased luciferase activity produced from *Luc-JunB* and *Luc-JunD* constructs in the presence of resveratrol, it failed to impair the downregulation of JunB by resveratrol, indicating that *miR-663*-independent effects were also taking place. This was probably due to the fact that resveratrol downregulates the pro-inflammatory nuclear factor-kappaB activity (32), which is needed for *JunB* activation (40). Also, *663-I* failed to increase JunB levels following LPS challenge. This is probably due in part to the fact that LPS challenge decreased *miR-663* levels. It is also possible that JunB might have already reached its maximum possible levels under LPS challenge in control experiment, that LPS may limit *miR-663* access to *JunB* transcripts or that *miR-663* might target transcripts encoding an unidentified repressor of *JunB*.

Importantly, *miR-663* also potentially targets transcripts encoding factors playing a role not only in toll-like receptor signaling and the innate immune response to LPS, but also in granulopoiesis, monopoiesis, interferon γ signaling, Th1 lymphocytes differentiation or TCR signaling. The functions of *miR-663* are thus probably not restricted to the monocyte/macrophage lineage.

Our results also show that *miR-663* impairs the upregulation of *miR-155* by LPS. This effect may be due to the targeting of JunB or FosB, which have been shown to transcriptionally activate *BIC*,

namely *miR-155* host gene (36). Also, *miR-663* potentially targets *KSRP* transcripts, which encode a RNA-binding protein implicated in the LPS-induced *miR-155* maturation from its primary transcripts *BIC* (41). Given the facts (i) that AP-1 factors participate to the activation of many pro-inflammatory cytokine genes in partnership with nuclear factor of activated T-cells factors (37) and are implicated in the upregulation of *miR-155* by LPS, (ii) that *miR-155* upregulation is a hallmark of innate immune response (21,22) and (iii) that *miR-663* levels decreased at the very beginning of LPS challenge (this manuscript), *miR-663* is probably to work along with *miR-146a* and *miR-146b* to control the intensity of the innate immune response. Furthermore, beside its roles in myeloid differentiation and innate response, *miR-155* has many other functions in the immune system, such as the regulation of myelopoiesis and erythropoiesis, Type 1 helper T-cells differentiation, B cell maturation, IgG1 production, somatic hypermutations, gene conversion, class switch recombination or B- and T-cell homeostasis (19). It will thus be very interesting to determine if *miR-663* can also modulate *miR-155* levels and functions in these different cell types.

Finally, the fact that resveratrol decreases both AP-1 activity and *miR-155* levels at least in part through the upregulation of *miR-663* could be critical in optimizing the use of resveratrol as an anti-inflammatory but also as an antitumor agent. Namely, several reports have recently established a direct link between elevated levels of *miR-155* expression and the formation and development of tumors such as leukemias and breast, lung or gastric cancers (19). Elevated *miR-155*

levels are linked with enhanced cell proliferation (16,17), transgenic mice with B cells overexpressing *miR-155* develop B-cell leukemia (25) and a sustained expression of *miR-155* in hematopoietic stem cells causes a myeloproliferative disorder (26). These transgenic mice also showed that one of the many effects of *miR-155* is the enhancement of cell proliferation. Of note, resveratrol impaired the upregulation of cyclins B1 and D3 by LPS (results not shown). This suggests that, beside opposing the proliferative effects of AP-1 factors, resveratrol may also oppose the proliferative activity of *miR-155* through the upregulation of *miR-663*. Importantly, *miR-663* was found to be downregulated in hormone refractory prostate cancer cells, along with *miR-146a* and *miR-146b* (42). Unfortunately, *miR-663* is not present in mouse genome, thus impairing direct experimentation using knock-out animals.

Nevertheless, while resveratrol anticarcinogenic potential has been linked with data primarily from human cell culture systems, evidence that resveratrol can inhibit carcinogenesis in several organ sites emerged from results of cancer prevention and therapy studies in laboratory animal models (29). However, previous results have shown that, at least when it comes to the immune system, the expression and thus potentially the function of miRNAs cannot be directly transposed from one species to another one. For example, the upregulation of anti-inflammatory *miR-146a* and *miR-146b* during the innate immune response has been observed only in human cell lines, such as THP-1 (20) or A549 cells (24), but not in mouse cell lines or in mouse spleen macrophage (22,43). As *miR-663* is found only in primates, our results come as a warning that studies in animal may not always allow to predict accurately the molecular effects of resveratrol in human.

Supplementary material

Supplementary Figures 1–3 and Tables I and II can be found at <http://carcin.oxfordjournals.org/>

Funding

Comprehensive Cancer Center of the Ohio State University; Ligue Française contre le Cancer, BIVB; Conseil Régional de Bourgogne.

Acknowledgements

Conflict of Interest Statement: None declared.

References

- Hussain,S.P. *et al.* (2007) Inflammation and cancer: an ancient link with novel potential. *Int. J. Cancer*, **121**, 2373–2380.
- Montovani,A. *et al.* (2008) Cancer-related inflammation. *Nature*, **454**, 436–444.
- Colotta,F. *et al.* (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*, **30**, 1073–1082.
- Schetter,A.J. *et al.* (2009) Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. *Carcinogenesis*, **31**, 37–49.
- Balkwill,F. *et al.* (2001) Inflammation and cancer: back to Virchow? *Lancet*, **357**, 539–545.
- Coussens,L.M. *et al.* (2002) Inflammation and cancer. *Nature*, **420**, 860–867.
- Ono,M. (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. *Cancer Sci.*, **99**, 1501–1506.
- Pollard,J.W. (2004) Tumor-educated macrophages promote tumor progression and metastasis. *Nat. Rev. Cancer*, **4**, 71–78.
- Yoshimura,A. (2006) Signal transduction of inflammatory cytokines and tumor development. *Cancer Sci.*, **97**, 439–447.
- Sica,A. *et al.* (2007) Altered macrophage differentiation and immune dysfunction: tumor development. *J. Clin. Invest.*, **117**, 1155–1165.
- Condeelis,J. *et al.* (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell*, **124**, 263–266.
- Lin,E.Y. *et al.* (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J. Exp. Med.*, **193**, 727–740.
- Ambros,V. (2004) The functions of animal miRNAs. *Nature*, **431**, 350–355.
- Calin,G.A. *et al.* (2006) MiRNA signatures in human cancers. *Nat. Rev. Cancer*, **6**, 857–866.
- Tili,E. *et al.* (2008b) MicroRNAs, the immune system and rheumatic disease. *Nat. Clin. Pract. Rheumatol.*, **10**, 534–541.
- Lindsay,M.A. (2008) microRNAs and the immune response. *Trends Immunol.*, **29**, 243–351.
- Tili,E. *et al.* (2008a) Expression and function of micro-RNAs in immune cells during normal or disease state. *Int. J. Med. Sci.*, **5**, 73–79.
- Tsitsiou,E. *et al.* (2009) microRNAs and the immune response. *Curr. Opin. Pharmacol.*, **9**, 514–520.
- Tili,E. *et al.* (2009) *miR155*: on the crosstalk between inflammation and cancer. *Int. Rev. Immunol.*, **28**, 264–284.
- Taganov,K.D. *et al.* (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc. Natl Acad. Sci. USA*, **103**, 12481–12486.
- O'Connell,R.M. *et al.* (2007) MicroRNA-155 is induced during the macrophage inflammatory response. *Proc. Natl Acad. Sci. USA*, **104**, 1604–1609.
- Tili,E. *et al.* (2007) Modulation of miR-155 and miR-125b levels following LPS/TNF- α stimulation, and their possible roles in regulating the response to endotoxin shock. *J. Immunol.*, **179**, 5082–5089.
- Rodriguez,A. *et al.* (2007) Requirement of *bic/microRNA-155* for normal immune function. *Science*, **316**, 608–611.
- Perry,M.M. *et al.* (2008) Rapid changes in microRNA-146a expression negatively regulate the IL-1 β -induced inflammatory response in human lung alveolar epithelium cells. *J. Immunol.*, **180**, 5689–5698.
- Costinean,S. *et al.* (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in *E(mu)-miR155* transgenic mice. *Proc. Natl Acad. Sci. USA*, **103**, 7024–7029.
- O'Connell,R.M. *et al.* (2008) Sustained expression of microRNA-155 in hematopoietic stem cell causes a myeloproliferative disorder. *J. Exp. Med.*, **205**, 585–594.
- Csiszar,A. *et al.* (2006) Resveratrol attenuates TNF α -induced activation of coronary arterial endothelial cells: role of NF- κ B inhibition. *Am. J. Physiol. Heart Circ. Physiol.*, **291**, H1694–H1699.
- Shankar,S. *et al.* (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. *Front. Biosci.*, **12**, 4839–4854.
- Bishayee,A. (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. *Cancer Prev. Res.*, **2**, 409–418.
- Athar,M. *et al.* (2007) Resveratrol: a review of preclinical studies for human cancer prevention. *Toxicol. Appl. Pharmacol.*, **224**, 274–283.
- Leiro,J. *et al.* (2004) Effects of *cis*-resveratrol on inflammatory murine macrophages: antioxidant activity and downregulation of inflammatory genes. *J. Leukoc. Biol.*, **75**, 1156–1165.
- Das,S. *et al.* (2007) Anti-inflammatory responses of resveratrol. *Inflamm. Allergy Drug Targets*, **6**, 168–173.
- Zhu,J. *et al.* (2008) Anti-inflammatory effect of resveratrol on TNF- α -induced MCP-1 expression in adipocytes. *Bioch. Bioph. Res. Commun.*, **369**, 471–477.
- Macian,F. *et al.* (2001) Partners in transcription: NFAT and AP-1. *Oncogene*, **20**, 2476–2489.
- Fujihira,M. *et al.* (1993) Mechanism of lipopolysaccharide-triggered *JunB* activation in a mouse macrophage-like cell line (J774). *J. Biol. Chem.*, **268**, 14896–14905.
- Yin,Q. *et al.* (2008) B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. *J. Biol. Chem.*, **283**, 2654–2662.
- Blank,V. *et al.* (1997) The Maf transcription factors: regulators of differentiation. *Trends Biochem. Sci.*, **22**, 437–441.
- Ozanne,B.W. *et al.* (2007) Transcription factors control invasion: AP-1 the first among equals. *Oncogene*, **26**, 1–10.
- Verde,P. *et al.* (2007) Deciphering AP-1 function in tumorigenesis: Fraternizing on target promoters. *Cell Cycle*, **6**, 2632–2639.
- Krappmann,D. *et al.* (2004) The I κ B kinase complex and NF- κ B act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. *Mol. Cell. Biol.*, **24**, 6488–6500.
- Ruggiero,T. *et al.* (2009) LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. *FASEB J.*, **23**, 2898–2908.
- Lin,S.-L. *et al.* (2008) Loss of miR-146a function in hormone-refractory prostate cancer. *RNA*, **14**, 417–424.
- Androulidaki,A. *et al.* (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. *Immunity*, **31**, 220–231.

Received December 17, 2009; revised May 15, 2010; accepted July 3, 2010